Stay updated with breaking news from Ossdsign Catalyst. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93%...
STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst. The data, that has been submitted to a peer-reviewed scientific journal, indicates that the use of OssDsign Catalyst lead
STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB announces that the portfolio company OssDsign expects revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary...
STOCKHOLM – 17 November 2023. Karolinska Development AB today publishes its Interim Report - January-September 2023. The full report is available on the Company's website. “It’s clear that our...
Ossdsign AB will abandon its 3D-printed cranial reconstructive implant business to focus on U.S. sales of its Ossdsign Catalyst, an off-the-shelf nanosynthetic bone graft that offers gross margins of 90% or better. The new strategy sharply reduces the capital required before the company projects achieving a cash-flow positive position.